Compare NUKK & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUKK | ZTEK |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.0M | 89.3M |
| IPO Year | N/A | N/A |
| Metric | NUKK | ZTEK |
|---|---|---|
| Price | $5.12 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 42.6K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $657,134.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2225.73 |
| 52 Week Low | $1.34 | $0.62 |
| 52 Week High | $78.32 | $1.84 |
| Indicator | NUKK | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 36.73 |
| Support Level | $5.89 | $0.70 |
| Resistance Level | $7.44 | $0.75 |
| Average True Range (ATR) | 0.87 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 14.10 | 12.10 |
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.